i am here sharing my ppt presentation on the design and development of in-situ gel in ophthalmic drug delivery system.

1. PRACTICE SCHOOL
A REVIEWON DESIGNANDDEVELOPMENTOF IN SITUOCCULARGEL IN
OPTHALMICDRUGDELIVARY SYSTEM
Submitted to
The West Bengal University of Health Sciences
Presented by
Sunipa Adak Reg no:-201901417
Suman Dhauria Reg no:-201901404
Suman Mishra Reg no:- 201901422
Suman Nanda Reg no:-202000322
B.Pharm, 4th Year, 7 Semester
Haldia Institute of Pharmacy
Under the guidance of
Miss Mahua Bera, M. Pharm
Assistant Professor, Haldia Institute of Pharmacy

2.  Introduction
 Challenges in ophthalmic drug delivery system in In situ gel
 Approaches for in situ gelling system
 Polymers used in In situ gel
 Aim and Objectives
 Methods of Formulation
Preparations
Materials
Instruments
 Evaluation
 Future aspect
 Conclusion
 Reference

3. OPTHALMIC DRUG DELIVERY SYSTEM:-
• Sterile liquid
• Semisolid or solid preparation
• Contain one or more active pharmaceutical ingredients
• Instilled in between eye lids and eye balls
GEL:-
• Containing both solid and liquid components
Components consists of three dimensional network
Fig:- GEL
Table:- Classifications of gel

4. INSITU GEL :-
• Process of gel formation
• Drug product exists as a liquid form
• Transformed from gel upon the contact with body fluid and body temperature
Advantages:-
• To provide sustained and controlled drug delivery.
• Increase accurate dosing to overcome the side effects of
pulsed dosing produced by conventional system
Disadvantages:-
• The drug solution stays very short time in the eye surface.
• It shows poor bioavailability

5. Challenges In situ gel in ophthalmic drug delivery system are to design a therapeutic system which can
provide an optimal concentration of a drug at the target region and with high therapeutic efficacy.
Most of the ocular drug challenging are poor in bioavailability due to , lacrimation , tear dilution,
precorneal residence time of the delivery system. That why in situ gel was prepared by different combination of drug
and excipient.

6. PHYSIOLOGICAL
STIMULI
PHYSICAL
STIMULI
CHEMICAL
STIMULI
Temperature
triggered In situ
gelling system
pH triggered
system
Solvent
exchange or
diffusion
Swelling
Osmosis
Enzymatic
Cross-linking
Photo
polymerization
Ionic cross-
linking
Bio-erosion

7. Classifications of polymers used in In situ gelling system:-
POLYMERS
Natural
Synthetic or
Semi
synthetic
Example:-Alginic acid,
Carrageenan, Guar
gum, Carbopol
Example:- HPMC,
Poloxamer , CAP

8. Natural Polymers:-
Polymers Uses
Alginic acid or sodium alginate  Thickening Agent
 Suspending Agent
Carbopol  Thickening Agent
 Stabilizing Agent
Synthetic or Semisynthetic:-
Polymers Uses
Poloxamer  In situ gelling vehicles to prolong the residence
time and better bioavailability of the ocular
drugs.
Hydroxy propyl methyl cellulose (HPMC):-  As hydrophilic matrices
 In combination with Carbopol , enhancing the
solution's viscosity while reducing the solution's
acidity.

9. AimS:-
The present investigation is to design and development of in situ gel in ocular drug
delivery system.
To increase the residence time and also sustain the release mechanisms of drugs.
ObjectiveS:-
The work design and development of in situ gel in ocular drug delivery system.
The objective of this work was to probably the contact time as the in situ gel will
be converted into aqueous upon contact with the eye.

10. Gel was prepared by two different methods, cold method and hot
method. Cold method is one of the preferred method, it provides
clear solution for in situ gel as well as it does not form lumps
polymer as it is reported and observed by hot process
Weight accurately poloxamer 407
Added cold water(5℃ ) with constant stirring
Each dispersion was refrigerated for 5 hrs at 5℃
Drug was added to clear solution at5℃
Mixed well to form homogenous mass
Concentration of polymer ranging from 14-22%
Drug and polymer Benzalkonium chloride ,was added as preservative
Triethanolamine was added to adjust pH of the formulation
Benzalkonium
chloride
Poloxamer 407
Cold water (5℃)
Triethanolamine
pH meter
Cold process

11. Weight HPMC and add 50 ml purified water
Add HPMCK15M and Carbopol934 solution hydrate over right
Solution stirrer and buffer salts(disodium hydrogen phosphate,
Citric acid) dissolved in solution
Drug dissolve and add water and Benzalkonium chloride
The make up volume 100 ml and sterilized autoclave for 20 min
Benzalkonium chloride
HPMCK15M
Carbopol934
Buffer salts(disodium
chloride, citric acid)
Purified water
Autoclave

12. Evaluation test
Measurement
of pH
Sterility
testing
Clarity and
appearance
Texture
analysis
Gelling
capacity
Viscosity
pH meter
Branches
Sterility test
apparatus
Sol-gel
Capacitor
dielectric
Clarity test
apparatus
Texture
analysis
apparatus
Brookfield
viscometer

13. M
 In the future, we expect the innovation of new and more reliable in situ forming polymers which
may be responsible to biological markers associated with disease condition of the eye.
 prolong precorneal resident time and offer the sustained release drug delivery, thus improve
ocular bioavailability and therapeutic efficacy and reduce systemic absorption and toxicity.
 The combination of two or more stimuli- responsive polymers in the same formulation is know to
exhibit greater compliance and improved therapeutic efficacy.

14. The present review concludes that in – situ gel system has emerged as one of the best novel drug delivery system.
In situ gelling systems are promising ocular delivery system because they can overcome the drawbacks associated
with conventional ocular dosage forms thus increasing patient compliance. The principle of these systems are the
possibility of administering accurate and reproducible quantities of drugs, increased pro corneal contact time,
prolonged drug release, drug delivery to deeper tissues, and reduced frequency of administration. They are easy to
administer, reduced dosing frequency, and good stability and biocompatibility characteristics have resulted in
increased patient comfort. Final, it can be concluded that in situ ocular gel is alternative to conventional eye drops.

15. 1. R. M MEHTA. Ophthalmic products: Pharmaceutics-2 ,4th.,Vallabh prakashan, Delhi, 2015,273-286.
2. Sarada K, Firoz S, Padmini k. IN- SITU GELLING SYSTEM. International journal of current pharmaceutical
Review and Research. (2014); 5(4): 76-90.
3. Harpreet Kaur, Sharnjeet Loyee, Rajeev Garg. FORMULATION AND EVALUATION OF IN – SITU GEL
OF GATIFLOXACIN. International Journal of Pharma Research and Health Sciences. (2016);4(5):1365-1370.
4. Majeed, Asmat & Khan, Nisar. . Ocular in situ gel: An overview. Journal of Drug Delivery and
Therapeutics.(2019); 9(1): 337-347. 10.22270/jddt.v9i1.2231.
5. priyanka m. borole, yogesh s.chaudhari, sanket s. dharashivkar, suresh d. kumavat, khushbu shenghani, pankit
r. shah. preparation and evaluation of in - situ gel of levofloxacin hemihydrate for treatment of periodontal
disease. international journal of pharmaceutical research and bio-science. (2013);2(3):185-196.
6. Khandelwal, Nikita & Bhide, Prashant & Nachinolkar, Reeshwa. formulation and evaluation of solubility
enhanced in situ gelling eye drops of loteprednol etabonate. Asian Journal of Pharmaceutical and Clinical
Research.(2019); 12(12): 209-216. 10.22159/ajpcr.2019.v12i12.33160.